Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Pharmacokinetic Study of Coagulation Factor Ⅷ in Adults with Severe Hemophilia A].

Zhongguo shi yan xue ye xue za zhi - 1 Oct 2024

Zhang Ying, Guo Zhi-Fang, Wang Jing-Jing, Lu Wen-Liang, Hao Jin-Yu, Wang Xin, Pan Zhi-Juan, Guo Yan-Ru, Guo Xin-Lei, Sun Jia-Jia, Jiang Bo, Li Zhi, Guo Zhi-Ping

Abstract excerpt

OBJECTIVE: To detect the pharmacokinetic (PK) parameters of coagulation factor Ⅷ (FⅧ) in adult patients with severe hemophilia A, identify the potential factors influencing FⅧ PK, and optimize the use of FⅧ in individual prophylaxis regimens. METHODS: PK characteristics of FⅧ were studied in a total of 23 severe hemophilia A adults. The correlation of patients' characteristics including age, von Willebrand factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemophilia A
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Genotype

Share to Half-Life

Share to von Willebrand Factor

Source

Identifiers

PMID: 39479840
DOI: 10.19746/j.cnki.issn.1009-2137.2024.05.032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Pharmacokinetic Study of Coagulation Factor Ⅷ in Adults with Severe Hemophilia A].PMID 39479840Read ↗

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.Semantic proximity Read ↗

Recent Advances in the Treatment of Hemophilia: A ReviewSemantic proximity Read ↗

Extending half-life in coagulation factors: where do we stand?Semantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Variable pharmacokinetics of coagulation factor VIII in the perioperative setting complicates personalisation of treatment in patients with haemophilia ASemantic proximity Read ↗

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.Semantic proximity Read ↗

[Screening and analysis of coagulation factor VIII inhibitor in patients with hemophilia A].Semantic proximity Read ↗

Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and ChallengesSemantic proximity Read ↗

Platelet Function and Microvesicles Generation in Patients with Hemophilia ASemantic proximity Read ↗

Long-term prophylaxis in severe factor VII deficiency.Semantic proximity Read ↗

In vitro evaluation of global coagulation potential in the copresence of emicizumab and warfarin in whole blood using rotational thromboelastometrySemantic proximity Read ↗

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.